» Articles » PMID: 23108553

Multiple Mechanisms Involved in the Large-spectrum Therapeutic Potential of Cannabidiol in Psychiatric Disorders

Overview
Specialty Biology
Date 2012 Oct 31
PMID 23108553
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound Δ(9)-tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric disorders such as anxiety, depression and psychosis. Although the pharmacological effects of CBD in different biological systems have been extensively investigated by in vitro studies, the mechanisms responsible for its therapeutic potential are still not clear. Here, we review recent in vivo studies indicating that these mechanisms are not unitary but rather depend on the behavioural response being measured. Acute anxiolytic and antidepressant-like effects seem to rely mainly on facilitation of 5-HT1A-mediated neurotransmission in key brain areas related to defensive responses, including the dorsal periaqueductal grey, bed nucleus of the stria terminalis and medial prefrontal cortex. Other effects, such as anti-compulsive, increased extinction and impaired reconsolidation of aversive memories, and facilitation of adult hippocampal neurogenesis could depend on potentiation of anandamide-mediated neurotransmission. Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD. Considering its safety profile and wide range of therapeutic potential, however, further studies are needed to investigate the involvement of other possible mechanisms (e.g. inhibition of adenosine uptake, inverse agonism at CB2 receptor, CB1 receptor antagonism, GPR55 antagonism, PPARγ receptors agonism, intracellular (Ca(2+)) increase, etc.), on CBD behavioural effects.

Citing Articles

Utilization of Cannabidiol in Post-Organ-Transplant Care.

Koyama S, Etkins J, Jun J, Miller M, So G, Gisch D Int J Mol Sci. 2025; 26(2).

PMID: 39859413 PMC: 11765766. DOI: 10.3390/ijms26020699.


Investigation of Cannabidiol's Protective Effects on Cadmium-Induced Toxicity in Mice.

Sahin S, Mortas T, Muderrisoglu A, Turksoy V Basic Clin Pharmacol Toxicol. 2025; 136(2):e14131.

PMID: 39832793 PMC: 11745803. DOI: 10.1111/bcpt.14131.


Medicinal Cannabis and the Intestinal Microbiome.

Vitetta L, Nation T, Oldfield D, Thomsen M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770543 PMC: 11678570. DOI: 10.3390/ph17121702.


Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.

Simei J, Souza J, Pedrazzi J, Guimaraes F, Campos A, Zuardi A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770486 PMC: 11677192. DOI: 10.3390/ph17121644.


Quantification of ∆9-tetrahydrocannabinol, 11-OH-THC, THC-COOH, hexahydrocannabinol, and cannabidiol in human plasma and blood by liquid chromatography-tandem mass spectrometry.

Pavlic M, Innerhofer C, Pitterl F J Anal Toxicol. 2024; 49(2):85-95.

PMID: 39656878 PMC: 11829072. DOI: 10.1093/jat/bkae094.


References
1.
Gururajan A, Taylor D, Malone D . Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. J Psychopharmacol. 2012; 26(10):1317-32. DOI: 10.1177/0269881112441865. View

2.
Resstel L, Joca S, Moreira F, Correa F, Guimaraes F . Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res. 2006; 172(2):294-8. DOI: 10.1016/j.bbr.2006.05.016. View

3.
Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G . Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2010; 114(2-3):242-5. DOI: 10.1016/j.drugalcdep.2010.09.020. View

4.
Bhattacharyya S, Crippa J, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P . Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012; 69(1):27-36. DOI: 10.1001/archgenpsychiatry.2011.161. View

5.
Leweke F, Schneider U, Radwan M, Schmidt E, Emrich H . Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav. 2000; 66(1):175-81. DOI: 10.1016/s0091-3057(00)00201-x. View